{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:18:54Z","timestamp":1789780734944,"version":"4.0.1"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01366","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T11:16:12Z","timestamp":1561115772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections"],"prefix":"10.3389","volume":"10","author":[{"given":"Orig\u00e8ne","family":"Nyanguile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet."},{"key":"B2","volume-title":"News\/Fact sheets\/Detail\/Influenza (Seasonal).","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the United States","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S0140-6736(12)61901-1","article-title":"Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis","volume":"381","author":"Nair","year":"2013","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1750-2659.2009.00073.x","article-title":"Estimates of US influenza-associated deaths made using four different methods","volume":"3","author":"Thompson","year":"2009","journal-title":"Influenza Other Respir Viruses."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14728210902946399","article-title":"Emerging drugs for respiratory syncytial virus infection","volume":"14","author":"Olszewska","year":"2009","journal-title":"Expert Opin Emerg Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Res."},{"key":"B10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.coviro.2016.03.002","article-title":"Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine","volume":"17","author":"Cho","year":"2016","journal-title":"Curr Opin Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science."},{"key":"B13","volume-title":"WHO Preferred Characteristics for Respiratory Syncytial Virus (RSV) vaccines.","author":"Martin","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr Opin Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1016\/j.vaccine.2017.05.045","article-title":"A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age","volume":"35","author":"August","year":"2017","journal-title":"Vaccine."},{"key":"B18","unstructured":"Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat Rev Drug Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005\u20132006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"Doc04","DOI":"10.3205\/id000030","article-title":"Influenza viruses\u2014Antiviral therapy and resistance","volume":"5","author":"Duwe","year":"2017","journal-title":"GMS Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1056\/NEJMp0900648","article-title":"Global transmission of oseltamivir-resistant influenza","volume":"360","author":"Moscona","year":"2009","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/jiq005","article-title":"Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010","volume":"203","author":"Sheu","year":"2011","journal-title":"J Infect Dis."},{"key":"B26","first-page":"461","article-title":"Zanamivir for the prevention of influenza in adults and children age 5 years and older","volume":"3","author":"Eiland","year":"2007","journal-title":"Ther Clin Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1126\/science.aan0516","article-title":"Potent peptidic fusion inhibitors of influenza virus","volume":"358","author":"Kadam","year":"2017","journal-title":"Science."},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/371037a0","article-title":"Structure of influenza haemagglutinin at the pH of membrane fusion","volume":"371","author":"Bullough","year":"1994","journal-title":"Nature."},{"key":"B29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu Rev Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev.bi.56.070187.002053","article-title":"The structure and function of the hemagglutinin membrane glycoprotein of influenza virus","volume":"56","author":"Wiley","year":"1987","journal-title":"Annu Rev Biochem."},{"key":"B31","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/S0021-9258(19)67772-0","article-title":"Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity","volume":"266","author":"Williams","year":"1991","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1073\/pnas.90.10.4374","article-title":"A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro","volume":"90","author":"Levi","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"B33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0006-291X(03)01131-8","article-title":"A peptide mimetic of an anti-CD4 monoclonal antibody by rational design","volume":"307","author":"Casset","year":"2003","journal-title":"Biochem Biophys Res Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/prot.340050104","article-title":"The construction of new proteins: V. A template-assembled synthetic protein (TASP) containing both a 4-helix bundle and beta-barrel-like structure","volume":"5","author":"Mutter","year":"1989","journal-title":"Proteins."},{"key":"B35","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.1073\/pnas.85.17.6488","article-title":"Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic\/antireceptor antibody: modeling of their three-dimensional structures","volume":"85","author":"Williams","year":"1988","journal-title":"Proc Natl Acad Sci USA."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science."},{"key":"B37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science."},{"key":"B38","doi-asserted-by":"publisher","first-page":"22008","DOI":"10.1038\/srep22008","article-title":"A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci Rep."},{"key":"B39","first-page":"103","article-title":"Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab","volume":"317","author":"Wu","year":"2008","journal-title":"Curr Top Microbiol Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jmb.2005.04.049","article-title":"Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization","volume":"350","author":"Wu","year":"2005","journal-title":"J Mol Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta12360","article-title":"Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation","volume":"12","author":"Wang","year":"2008","journal-title":"Health Technol Assess."},{"key":"B42","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2018.1470727","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","volume":"10","author":"Larios Mora","year":"2018","journal-title":"MAbs."},{"key":"B43","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01714","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci Immunol."},{"key":"B46","unstructured":"Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants."},{"key":"B47","volume-title":"Analysis of Presatovir (GS-5806) Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected with Respiratory Syncytial Virus.","author":"Jordan","year":"2015"},{"key":"B48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat Commun."},{"key":"B51","article-title":"EDP-938, a novel non-fusion replication inhibitor of RSV, displays high barrier for resistance to RSV in vitro","volume-title":"11th International Respiratory Syncytial Virus Symposium, Omni Grove Park Inn.","author":"Rhodin","year":"2018"},{"key":"B52","article-title":"Low rate of resistance to the RSV fusion inhibitor RV521 in human infection","volume-title":"11th International Respiratory Syncytial Virus Symposium, Omni Grove Park Inn.","author":"DeVincenzo","year":"2018"},{"key":"B53","unstructured":"J&J Dumps Alios RSV Drug, Wiping Remaining $900M off Value."},{"key":"B54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of respiratory syncytial virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat Chem Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"14172","DOI":"10.1073\/pnas.260499197","article-title":"Structural characterization of the human respiratory syncytial virus fusion protein core","volume":"97","author":"Zhao","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B56","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1128\/jvi.74.13.5911-5920.2000","article-title":"The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil","volume":"74","author":"Matthews","year":"2000","journal-title":"J Virol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.93.5.2186","article-title":"Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion","volume":"93","author":"Lambert","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ab.2010.10.020","article-title":"A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform","volume":"409","author":"Park","year":"2011","journal-title":"Anal Biochem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1172\/JCI71856","article-title":"Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection","volume":"124","author":"Bird","year":"2014","journal-title":"J Clin Invest."},{"key":"B61","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nprot.2011.324","article-title":"Synthesis of all-hydrocarbon stapled \u03b1-helical peptides by ring-closing olefin metathesis","volume":"6","author":"Kim","year":"2011","journal-title":"Nat Protoc."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-396962-0.00001-X","article-title":"Stapled peptides for intracellular drug targets","volume":"503","author":"Verdine","year":"2012","journal-title":"Methods Enzymol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e02241","DOI":"10.1128\/AAC.02241-16","article-title":"A short double-stapled peptide inhibits respiratory syncytial virus entry and spreading","volume":"61","author":"Gaillard","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B65","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/psc.1328","article-title":"DPP-IV-resistant, long-acting oxymtomodulin derivatives","volume":"17","author":"Santoprete","year":"2010","journal-title":"J Pept Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"43610","DOI":"10.1038\/srep43610","article-title":"Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides","volume":"7","author":"Mathieu","year":"2017","journal-title":"Sci Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1001168","DOI":"10.1371\/journal.ppat.1001168","article-title":"Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry","volume":"6","author":"Porotto","year":"2010","journal-title":"PLoS Pathog."},{"key":"B68","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1128\/JVI.00135-10","article-title":"Viral entry inhibitors targeted to the membrane site of action","volume":"84","author":"Porotto","year":"2010","journal-title":"J Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e36833","DOI":"10.1371\/journal.pone.0036833","article-title":"A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity","volume":"7","author":"Pessi","year":"2012","journal-title":"PLoS ONE."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg Med Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today."},{"key":"B72","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","article-title":"Future directions for peptide therapeutics development","volume":"18","author":"Kaspar","year":"2013","journal-title":"Drug Discov Today."},{"key":"B73","first-page":"779","article-title":"Current trends in the clinical development of peptide therapeutics","volume":"12","author":"Saladin","year":"2009","journal-title":"IDrugs."},{"key":"B74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/science.7529940","article-title":"A hot spot of binding energy in a hormone\u2013receptor interface","volume":"267","author":"Clackson","year":"1995","journal-title":"Science."},{"key":"B75","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/cb300515u","article-title":"Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints","volume":"8","author":"Bock","year":"2013","journal-title":"ACS Chem Biol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1021\/jm401859b","article-title":"High throughput method for the indirect detection of intramolecular hydrogen bonding","volume":"57","author":"Goetz","year":"2014","journal-title":"J Med Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"14073","DOI":"10.1021\/ja063076p","article-title":"Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides","volume":"128","author":"Rezai","year":"2006","journal-title":"J Am Chem Soc."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1021\/ja0563455","article-title":"Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers","volume":"128","author":"Rezai","year":"2006","journal-title":"J Am Chem Soc."},{"key":"B79","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nchembio.664","article-title":"On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds","volume":"7","author":"White","year":"2011","journal-title":"Nat Chem Biol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T04:11:07Z","timestamp":1609992667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2019.01366"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01366","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"article-number":"1366"}}